

ASX RELEASE

Notification of Release of Restricted Securities from Escrow

Melbourne, Australia, 23 July 2019: [Sienna Cancer Diagnostics Ltd \(ASX: SDX\)](#) (“Sienna” or “the Company”), a medical technology company developing and commercialising innovative cancer-related tests, wishes to advise, in accordance with ASX Listing Rule 3.10A, that 24,426,629 fully paid ordinary shares will be released from a 24 month period of escrow on 3 August 2019. These shares were mandatorily escrowed when the Company listed on the ASX on 3 August 2017.

Sienna will apply for quotation of the 24,426,629 fully paid ordinary shares following release from escrow in accordance with the ASX Listing Rules.

ENDS

For further information, please contact:

Matthew Hoskin, CEO
Sienna Cancer Diagnostics
mhoskin@siennadiagnostics.com.au
+61 3 8288 2141

Kyahn Williamson
WE Buchan
sienna@we-buchan.com
+61 3 8866 1200

About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd. is an Australian medical technology company with operations in the United States, Europe, Asia, Latin America and Australia. Sienna’s strengths lie in the identification, development and commercialisation of novel IVD technologies that satisfy an unmet clinical / market need. The Company has taken its first product, an IVD test for the biomarker hTERT, from research, through development, manufacturing, product registration, and market launch through a growing network of distribution partners.

The Company is focused on growing revenues from the existing product, increasing market access through new distribution partners, extending the applications for their hTERT test, and expanding their product offerings with the addition of new technologies into the product development pipeline.

Sienna’s most recent technology acquisition was a unique technology for the capture and isolation of target analytes in liquid biopsy samples. The sample preparation technology, known as SIEN-NET™ can more accurately and rapidly prepare liquid biopsy samples for the testing of a range of clinically useful biomarkers including exosomes, lipids, proteins, and other molecular targets of interest.

